Similarly to prior studies, our results also demonstrate the increased number of TLR4- and CD14-positive cells and the increased serum TNF-α and IL-6 levels in the NASH group, supporting the potential role of PAMPs in the development of NASH. The gene discussed is CD14; the disease is metabolic dysfunction-associated steatohepatitis.